Abbas Kazimi is the Chief Executive Officer and a member of the Board of Directors at Nimbus Therapeutics. Previously, he served as Chief Business Officer, leading the company’s strategic and corporate development efforts while overseeing business operations. Since joining Nimbus in 2014, he has helped raise over $630 million in equity financing and led  transactions totaling more than $8 billion.

Notably, Mr. Kazimi spearheaded the $6 billion sale of Nimbus’s TYK2 program to Takeda, the $1.2 billion sale of its NASH (ACC) program to Gilead, and multiple licensing deals exceeding $1.5 billion with partners such as Genentech, Celgene/Roche, and Eli Lilly. Under his leadership, Nimbus has advanced four programs into the clinic, returned over $4 billion to investors, and continues to expand its computational drug discovery and clinical development capabilities.

Mr. Kazimi currently serves on the board of Unnatural Products (UNP), a biotech company pioneering orally delivered macrocyclic peptides for previously undruggable targets. He is also on the Editorial Advisory Board for In Vivo magazine, a leading publication focused on strategic insights and analysis for the pharmaceutical and biotechnology industries.

Prior to Nimbus, Mr Kazimi was at Extera Partners, LLC (formerly PureTech Development, LLC), where he provided strategic advisory, supported fundraising, and executed numerous business development transactions. Earlier in his career, he was with JSB-Partners, LP, a specialized investment banking and advisory firm serving biotech and pharmaceutical companies.

Mr. Kazimi holds a B.A. from the University of Texas at Austin and an M.S. from Harvard University.

John has more than 20 years of legal experience in life sciences R&D, chemistry, medical devices, and patent prosecution. Before joining Nimbus, John served as Senior Intellectual Property Counsel at Amgen, where he provided intellectual property (IP) support for Otezla^® (apremilast). Prior to Amgen, he spent 10 years as a patent attorney at Novartis Institutes for BioMedical Research (NIBR) supporting various therapeutic areas including ophthalmology, infectious disease, and cardiovascular and metabolic disease. While at NIBR, John defined and implemented the initial IP strategy for FABHALTA^® (iptacopan). John began his career as a technology specialist, patent agent, and patent attorney at Edwards, Angell Palmer & Dodge, LLP. He holds a JD from Suffolk University Law School, a PhD in inorganic chemistry from the Massachusetts Institute of Technology under the direction of Nobel laureate Richard R. Schrock, and a bachelor’s degree in chemistry from Dartmouth College.

Todd brings more than 20 years of biopharmaceutical and non-profit experience in the discovery and development of novel therapeutics across oncology, infectious disease, neurodegeneration, and inflammation. As Vice President of Program Management and R&D Strategic Operations at Nimbus, he leads cross-functional R&D teams and strategic initiatives to advance the company’s pipeline. Prior to Nimbus, Todd served as Program Management Leader at the Bill & Melinda Gates Medical Research Institute, focused on biologic and vaccine development for global health, and as Vice President of Portfolio and Program Leadership at Mersana Therapeutics. He previously held progressive leadership roles at H3 Biomedicine, Cyteir Therapeutics, and Paratek Pharmaceuticals, managing discovery and development programs from early research through clinical development. Todd earned a PhD in Mechanistic Enzymology from Baylor University and a BA in Biology from Franklin & Marshall College.

Before joining Nimbus, Scott served as the Director and Head of Boston Oncology Chemistry at AstraZeneca, where he led a team of over 40 internal chemists and 25 CRO chemists to execute on oncology drug discovery programs from target validation through candidate discovery. He also co-led the Global Oncology PROTACs effort to help establish and grow a promising new modality. Before AstraZeneca, he held several positions of increasing responsibility at Merck, focusing on projects in the early discovery space (target validation, lead identification) through late-stage discovery and beyond. Over the course of his career, he has authored and co-authored over 50 publications in peer-reviewed journals and over 55 patents and patent applications. He has led teams who have delivered over a dozen clinical candidates and two marketed drugs. Scott earned his bachelor’s degree in chemistry from Cornell University and his PhD from The Ohio State University with Professor Leo Paquette, moving to Columbia University for an NIH postdoctoral fellowship with Professor Samuel Danishefsky.

Cindy brings more than 15 years of experience in biotech communications, medical affairs, and strategic operations. As Vice President of Corporate Affairs & Communications at Nimbus, she partners with the CEO and Executive Team to drive organizational alignment and leads internal and external communications. Prior to Nimbus, Cindy was Head of Strategic Communications at Shape Therapeutics, where she led investor relations, media strategy, and scientific communications. She previously held leadership roles in medical affairs and communications at Wave Life Sciences, Sanofi, and Biogen. Earlier in her career, she was a biopharma market research analyst at Decision Resources and a consultant at Accenture. Cindy earned a PhD in Cellular, Molecular and Biophysical Studies from Columbia University and a BS in Chemical Engineering with a minor in Writing from MIT.

Neelu is a medicinal chemist with more than 30 years of experience in the pharmaceutical industry. She joined Nimbus in 2017 following a 23-year tenure at Pfizer/Wyeth where she worked across multiple therapeutic areas. Her R&D experience spans several target classes including kinases, GPCRs, and lipases. She has executed programs through various drug discovery stages to deliver clinical candidates. Neelu has led multidisciplinary teams of chemists, biologists, pharmacokinetic scientists, toxicologists, and external collaborators that have delivered six development candidates and one marketed drug, CIBINQO^® (aberocitnib) for atopic dermatitis. Neelu has authored and co-authored 58 publications in peer-reviewed journals and 26 patents and patent applications. She earned her bachelor’s and master’s degree in chemistry from Delhi University. She holds a PhD in organic chemistry from City University of New York-Hunter College.

Before joining Nimbus, Avinash held numerous roles of increasing responsibility in chemistry and CMC at Achillion Pharmaceuticals, most recently as Vice President, Head of CMC. He and his team discovered eight clinical candidates, developed manufacturing processes, and oversaw the manufacturing of these investigational therapeutics across various stages of clinical development for the treatment of Hepatitis C and PNH. Previously, he served as a research chemist at Miravant Pharmaceuticals and a scientist at Antivirals Inc. He has authored/co-authored more than 30 publications and holds over 60 patents/patent applications. Avinash earned a bachelor’s degree in chemistry from Pune University, a master’s degree in chemistry from Indian Institute of Technology, Mumbai, and a PhD in organic chemistry from Pune University. He was a postdoctoral fellow with Professor H.C. Brown at Purdue University.

Dan joined Nimbus following a 16-year tenure at GSK, where he most recently served as Director, Computational Chemistry. At GSK, Dan contributed to the discovery of four clinical-stage drug candidates in distinct therapeutic areas. In addition to his expertise in structure-based drug discovery and ligand-based drug discovery, Dan has specialized experience in kinase targeting, cross-domain informatics, and ADME modeling. He earned his PhD in molecular biophysics and biochemistry from Yale University and a bachelor’s degree in chemical engineering from the University of Colorado, Boulder. He completed his postdoctoral research fellowship at the Scripps Research Institute.

Before joining Nimbus, Ian served as CFO of Boston Pharmaceuticals, where he was responsible for financial strategy and operations and was recognized by Boston Business Journal as “Small Company CFO of the Year” in 2019. He previously was CFO at Catabasis Pharmaceuticals, where he led the re-positioning and successful IPO of the company and prior to that, spent 20 years with Cowen and Company, most recently as a Senior Pharmaceuticals Analyst, leading their emerging and specialty pharmaceuticals research team. While at Cowen, he was named to several Institutional Investor Analyst All-Star teams for coverage of the specialty pharmaceuticals sector and helped build one of the top-ranked healthcare research teams on Wall Street. Prior to his pharmaceuticals research analyst career, he was a healthcare investment banker with Cowen and Houlihan Lokey. Ian earned a bachelor’s degree in political economy from Williams College and an MBA in finance from the Wharton School. He is the treasurer and a director of Youth Enrichment Services in Boston, an organization which provides outdoor experiences and educational opportunities to inner-city adolescents. He also serves as a director of the Kelly Brush Foundation, which helps people with spinal cord injuries obtain adaptive athletic equipment to lead active lives.

Anita has more than 15 years of experience in the pharmaceutical industry leading oncology clinical development strategy and execution on more than a dozen programs. She has extensive experience in small molecule and immuno-oncology drug development, ranging from early discovery and pre-candidate selection to late-stage development across different tumor types at both small biotechnology and large pharmaceutical companies. Prior to joining Nimbus, Anita provided strategic consulting to biotechnology companies, developing clinical development strategies for multiple early-stage oncology assets. Previously, she served as Vice President and Head of Clinical Development, Oncology at Trillium Therapeutics (acquired by Pfizer). She also previously served as Vice President of Clinical Development, Oncology at Boston Pharmaceuticals. Before that, Anita held leadership roles of increasing responsibility at Pfizer and GSK. Anita earned her MD from the University of Zurich and her PhD in neurosciences from Pierre and Marie Curie (now Sorbonne) University in Paris. She completed a postdoctoral fellowship at Harvard Medical School and residencies at Cantonal Hospital in Lucerne and University Hospital Zurich in Switzerland.

Steve brings to Nimbus more than 25 years of experience implementing innovative digital and cybersecurity solutions and processes, enabling biotechnology companies to realize and benefit from their strategic goals. His prior roles include Chief Information Security Officer at Orchard Therapeutics and Executive Director of Enterprise Architecture at AMAG Pharmaceuticals. Steve’s depth of experience ranges from digital transition and information security planning to enterprise risk, mergers, business process continuity, governance, and policy design. Steve received bachelor’s degrees in history and business administration from the University of Massachusetts, Amherst and Western New England University, respectively.

Peter Tummino is the President of Research and Development at Nimbus Therapeutics, where he leads the Discovery, Nonclinical and Clinical groups. Since joining Nimbus as Chief Scientific Officer in 2019, he has been part of the leadership team. In his time at Nimbus, the company has successfully progressed the TYK2 inhibitor NDI-4858 through Phase 2 trials for psoriasis and other immunology indications, advanced the HPK1 inhibitor NDI-101150 through Phase 1b trials in solid tumors, and initiated Phase 1 trials for the WRN inhibitor NDI-219216 in MSI-high solid tumors.

Peter brings over 30 years’ experience in drug discovery across a range of therapeutic areas. Prior to Nimbus, he served as Vice President, Global Head of Lead Discovery at Janssen Pharmaceuticals, leading global discovery operations across multiple therapeutic areas. At GlaxoSmithKline, he held leadership roles including Head of Biology for the Cancer Epigenetics Discovery Performance Unit, progressing first-in-class epigenetic agents into oncology clinical trials. His contributions at GSK included the discovery and progression of several clinical candidates, including the approved oncology drugs dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor), and daprodustat for chronic kidney disease. Earlier, he held scientific positions of increasing responsibility at Warner-Lambert/Parke-Davis, AstraZeneca, and Millennium Pharmaceuticals. He has published 85 peer-reviewed journal articles with over 15,000 citations. Peter earned his B.S. in Chemistry from the University of Massachusetts and his Ph.D. from the Department of Biological Chemistry at the University of Michigan, completing a postdoctoral fellowship at Warner-Lambert/Parke-Davis.